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Abstract
Background: Gastro-Intestinal stromal tumours (GISTs) are rare and our understanding of their
natural history and optimal treatment are continually evolving. Port site metastasis after
laparoscopy for a GIST is an extremely rare phenomenon.
Case presentation: We report a case with relevant imaging and discuss factors that may have
contributed to the development of this isolated metastasis.
Conclusion: Percutaneous methods of sampling GIST tumours for analysis should be avoided if at
all possible. When necessary, prophylactic measures should be utilised to minimise the risk of
seeding.
Background
Gastro-Intestinal stromal tumors (GISTs) are rare, and our
understanding of their natural history and optimal treat-
ment are continually evolving. This case report of a port
site metastasis following laparoscopy for a malignant
GIST is, to our knowledge, only the second documented
case. As well as an outline of the case itself, the question
as to why these arise and what the optimal treatment
should be is also discussed.
Case presentation
A 75 year old female presents to her General Practitioner
with symptoms of lethargy, weight loss and occasional
vomiting. Abdominal examination reveals a large mass in
the epigastrium and blood investigations reveal a micro-
cytic anaemia with a Haemoglobin of 9.4 g/dL. Her only
past medical history includes atrial fibrillation and a total
abdominal hysterectomy and bilateral salpingo-
oophorectomy for benign disease.
She is urgently referred for further investigation. Com-
puted Tomography (CT) scanning demonstrates a 13 cm
multi-loculated mass adjacent to the anterior wall of the
stomach radiologically suspicious for a Gastro-intestinal
stromal tumour (GIST). A subsequent PET-CT scan also
demonstrated multiple peritoneal seedlings (Figure 1).
Upper Gastro-intestinal Endoscopy showed extrinsic
compression of anterior gastric wall, with possible com-
munication to a pus filled cavity. Unfortunately, multiple
biopsies failed to yield a histological diagnosis.
At diagnostic laparoscopy (performed to obtain tissue
diagnosis and assess potential tumour stage), the large
mass anterior to the stomach was biopsied as were the
peritoneal seedlings. Histology demonstrated a malignant
GIST, strongly positive for CD117. She was discussed at
the regional Upper GI Multi-Disciplinary meeting, and
the decision made to commence systemic oncological
therapy with Glivec (Imatinib).
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Encouragingly, her response to treatment was excellent
and within one month a demonstrable radiological
improvement was noted (Figure 2). At ten months there
was no evidence of residual disease on PET-CT (Figure 3).
As per unit procedure, she subsequently entered a routine
follow up protocol which included regular clinical and
radiological review.
Unfortunately, although she remains clinically asympto-
matic, a follow up PET-CT (approximately 22 months
from initial diagnosis and commencement of treatment)
demonstrated a small discrete focus of uptake within the
internal oblique muscle on the right side (Figure 4). This
correlates with the location of the port site used at the
time of diagnostic laparoscopy.
In light of the confirmation of a port site metastasis
(PSM), she is due to be discussed again in the MDT meet-
ing prior to making a final decision regarding further
treatment. The evidence base for the treatment of port site
recurrences originating from common tumours is limited.
In the context of this particular case i.e. a GI Stromal
tumour, it is non-existent.
Discussion
Gastro-intestinal stromal tumours are the most common
mesenchymal tumour affecting the GI tract. They may
present in a variety of ways, can range from small to very
large and demonstrate a great diversity in their malignant
potential. Tumours are often positive for the c-KIT
(CD117) protein which is a tyrosine kinase receptor and
is the most sensitive and specific marker. Mutations of this
CD117 proto-oncogene are associated with stromal
tumours and hence the use of long term Imatinib (a
CD117 inhibitor) in their treatment [1].
In many ways, the presentation in this case with a malig-
nant GIST is fairly typical. Bleeding, and resultant anae-
mia, is often the precipitating event leading up to
presentation. Malignant tumours often have a palpable
mass at diagnosis and response to Glivec (although some-
what variable) can be dramatic.
Generally speaking, pre-operative biopsy is not advised in
patients who are radiologically diagnosed with a GIST and
resectable. However, in the event of more widespread dis-
ease, where histological confirmation is required to com-
mence oncological treatment, endoscopic biopsy
techniques are preferred in order to limit the possibility of
peritoneal contamination. Failing this, percutaneous tech-
niques (either radiologically guided or via laparoscopy)
remain the only alternative, both presenting a theoretical
risk of tumour seeding [2,3].
Port Site metastases (PSM) although rare, have been
extensively documented for other gynaecological and GI
malignancies. When they occur, they often do so in the
presence of advanced disease, and it is not uncommon for
them to occur in isolation [4,5]. Their presence is usually
associated with poor long term outcomes.
Advanced tumour with uptake seen within a large mass and throughout the peritoneal cavity Figure 1
Advanced tumour with uptake seen within a large mass and throughout the peritoneal cavity.
Partial Response with significantly reduced uptake on PET Figure 2
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Mechanisms thought to be involved in the development
of PSMs include high pressure CO2 insufflation, the
degree of tumour manipulation during surgery, direct
seeding during unprotected tumour/instrument with-
drawal as well as the biological characteristics of the can-
cer itself [6,7].
In this particular case, laparoscopy (and hence gas insuf-
flation) was required because of failure of alternative tech-
niques to establish the diagnosis. The tumour was
biopsied and the biopsy instrument removed through the
port (in theory protecting the specimen from contacting
the layers of the abdominal wall), although the port itself
then required removal. The advanced nature of the
tumour also increased the risk of a PSM but as far as we
know, the port did not enter the peritoneal cavity at the
site of an existing peritoneal metastasis.
As far as the authors are aware, there is only one previ-
ously documented case of port site metastasis (PSM) fol-
lowing laparoscopy for a stromal tumour [8]. Although an
extremely rare phenomenon, the implication is that pro-
phylactic measures of preventing seeding should be
undertaken when performing laparoscopy for stromal
tumours. Such measures could include the use of protec-
tive retrieval bags or peritoneal lavage with anti-adhesive
or cytocidal solutions, although evidence for the latter is
limited to say the least. Where possible, the use of any per-
cutaneous technique to obtain diagnosis should be
avoided.
In this particular case, further treatment options could
include surgical resection of the port site or the use of a
second line agent such as sunitinib. This latter decision
would be made on the assumption that the development
of a port site metastasis whilst on first line treatment, con-
fers the development of tumour resistance to this intial
therapy. This is a phenomenon that has been increasingly
well documented in the literature [1], and successfully
treated with further medical therapy.
Conclusion
Percutaneous methods of obtaining histological evidence
of GIST tumours, should be avoided if at all possible.
When necessary, the reporting of PSM's suggests that pro-
phylactic measures should be utilised to minimise the risk
of seeding.
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No residual tumour Figure 3
No residual tumour. No pathological uptake seen within the abdominal cavity.
Port site metastasis Figure 4
Port site metastasis. Uptake can be clearly seen in the Abdominal wall (Internal oblique) corresponding to the site of the lapar-
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